Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
NCT ID: NCT03558386
Last Updated: 2020-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
92 participants
OBSERVATIONAL
2018-07-23
2019-11-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients between 55-64 years of age
Patients between 55-64 years who have had a transplant at the following time points:
* 6 months to 1 year ago
* 1 year to 3 years ago
* 3 years ago or more
ePRO survey
An electronic patient reported outcomes survey will be completed by the patient.
Patients 65+ years of age
Patients 65+ years of age who have had a transplant at the following time points:
* 6 months to 1 year ago
* 1 year to 3 years ago
* 3 years ago or more
ePRO survey
An electronic patient reported outcomes survey will be completed by the patient.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ePRO survey
An electronic patient reported outcomes survey will be completed by the patient.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Underwent an allogeneic HCT for MDS on the 10-CMSMDS-1 protocol
2. Prior consent to research and future contact by the CIBMTR
3. Ability to provide RCI BMT protocol 17-ePRO signed and dated informed consent form (ICF)
4. Age ≥55 years at time of transplant
5. Fluent in English or Spanish
6. Greater than 6 months post-HCT
Exclusion Criteria
1. No access to an internet browser or email account
2. Within 6 months of first HCT for MDS on the 10-CMSMDS-1 protocol
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Medical College of Wisconsin
OTHER
Center for International Blood and Marrow Transplant Research
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bronwen E Shaw, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Center for International Blood and Marrow Transplant Research (CIBMTR)/Medical College of Wisconsin
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford University
Stanford, California, United States
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
The Ohio State University
Columbus, Ohio, United States
Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
17-ePRO
Identifier Type: -
Identifier Source: org_study_id